Gilead Sciences, Inc. vs Manhattan Associates Inc — how do they compare? Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B), while Manhattan Associates Inc trades at $195 (market cap $11.38B). The key difference: Gilead Sciences, Inc. is far larger — about 14.8× Manhattan Associates Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals.
| GILD | MANH | |
|---|---|---|
Market Cap | $168.35B | $11.38B |
Sector | Health | Technology |
52-Week High | $155.80 | $220.19 |
52-Week Low | $110.56 | $120.88 |
Enterprise Value | $191.42B | $11.25B |
Dividend Yield | 2.42% | — |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →